LOW FLAT RATE AUST-WIDE $9.90 DELIVERY INFO

Close Notification

Your cart does not contain any items

The Quest for Human Longevity

Science, Business, and Public Policy

Lewis D. Solomon

$284

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Transaction Publishers
30 September 2005
The Quest for Human Longevity considers scientific studies by exploring the principal biomedical anti-aging techniques, and cutting edge research on mental enhancements and assesses the scientific doubts of skeptics. Of interest to policymakers, sociologists, scientists, and students of business.
By:  
Imprint:   Transaction Publishers
Country of Publication:   United Kingdom
Dimensions:   Height: 229mm,  Width: 152mm,  Spine: 19mm
Weight:   453g
ISBN:   9780765803009
ISBN 10:   0765803003
Pages:   208
Publication Date:  
Audience:   College/higher education ,  Professional and scholarly ,  Professional & Vocational ,  A / AS level ,  Further / Higher Education
Format:   Hardback
Publisher's Status:   Active
1: The Second Longevity Revolution; 2: The Ups and Downs of Telomeres and Telomerase: Geron Corp.; 3: Oxidative Damage from Free Radicals and the Anti-Oxidant Antidote: Juvenon, Inc. and Eukarion, Inc.; 4: Caloric Restriction and Its Mimics: BioMarker Pharmaceuticals, Inc.; 5: Genetic Manipulation, Its Mimics, and Biochemical Activators: Elixir Pharmaceuticals, Inc.; 6: The Search for Memory-Enhancing Drugs: Helicon Therapeutics, Inc., Memory Pharmaceuticals Corp., and Cortex Pharmaceuticals, Inc.; 7: Life Extension: Public Policy Aspects

Lewis D. Solomon is Theodore Rinehart Professor of Business Law at George Washington University Law School. A prolific author on legal, business, public policy, and religious topics, he has written over fifty books and numerous articles. He is an ordained rabbi and interfaith minister.

Reviews for The Quest for Human Longevity: Science, Business, and Public Policy

The Quest for Human Longevity , which describes, in great detail, the importance of money in the entrepreneurial business of life-extension and antiaging research. In the view of the author, Lewis D. Solomon, financial incentives often drive scientific innovations in antiaging studies by stimulating researchers to take risks and work hard. The Quest for Human Longevity lifts the curtain of secrecy regarding financial matters by providing a detailed history of eight corporations that are pursuing antiaging and life-extension interventions....will be of interest to medical students, scientists involved in bio-medical research on aging, policymakers, and biotech investors, as well as to general readers interested in compelling issues of future life extension and debates over commercialized science. --Leonid Gavrilov and Natalia Gavrilova, The New England Journal of Medicine The Quest for Human Longevity , which describes, in great detail, the importance of money in the entrepreneurial business of life-extension and antiaging research. In the view of the author, Lewis D. Solomon, financial incentives often drive scientific innovations in antiaging studies by stimulating researchers to take risks and work hard. The Quest for Human Longevity lifts the curtain of secrecy regarding financial matters by providing a detailed history of eight corporations that are pursuing antiaging and life-extension interventions....will be of interest to medical students, scientists involved in bio-medical research on aging, policymakers, and biotech investors, as well as to general readers interested in compelling issues of future life extension and debates over commercialized science. --Leonid Gavrilov and Natalia Gavrilova, The New England Journal of Medicine The Quest for Human Longevity, which describes, in great detail, the importance of money in the entrepreneurial business of life-extension and antiaging research. In the view of the author, Lewis D. Solomon, financial incentives often drive scientific innovations in antiaging studies by stimulating researchers to take risks and work hard. The Quest for Human Longevity lifts the curtain of secrecy regarding financial matters by providing a detailed history of eight corporations that are pursuing antiaging and life-extension interventions....will be of interest to medical students, scientists involved in bio-medical research on aging, policymakers, and biotech investors, as well as to general readers interested in compelling issues of future life extension and debates over commercialized science. --Leonid Gavrilov and Natalia Gavrilova, The New England Journal of Medicine The Quest for Human Longevity, which describes, in great detail, the importance of money in the entrepreneurial business of life-extension and antiaging research. In the view of the author, Lewis D. Solomon, financial incentives often drive scientific innovations in antiaging studies by stimulating researchers to take risks and work hard. The Quest for Human Longevity lifts the curtain of secrecy regarding financial matters by providing a detailed history of eight corporations that are pursuing antiaging and life-extension interventions....will be of interest to medical students, scientists involved in bio-medical research on aging, policymakers, and biotech investors, as well as to general readers interested in compelling issues of future life extension and debates over commercialized science. --Leonid Gavrilov and Natalia Gavrilova, The New England Journal of Medicine -The Quest for Human Longevity, which describes, in great detail, the importance of money in the entrepreneurial business of life-extension and antiaging research. In the view of the author, Lewis D. Solomon, financial incentives often drive scientific innovations in antiaging studies by stimulating researchers to take risks and work hard. The Quest for Human Longevity lifts the curtain of secrecy regarding financial matters by providing a detailed history of eight corporations that are pursuing antiaging and life-extension interventions....will be of interest to medical students, scientists involved in bio-medical research on aging, policymakers, and biotech investors, as well as to general readers interested in compelling issues of future life extension and debates over commercialized science.- --Leonid Gavrilov and Natalia Gavrilova, The New England Journal of Medicine


See Also